Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Madrigal Pharmaceuticals Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are handled by 3 distinct examiners, meaning each examiner is responsible for one pending matter. The portfolio is slightly more concentrated at the administrative level, with the 3 actions residing in 2 distinct art units.
MOU, LIYUAN is the busiest examiner, holding 1 pending office action. Given the 3 pending office actions total, the company's current prosecution footprint is small. Practitioners must engage with 3 distinct examiners, but the fact that they are located in only 2 distinct art units may provide some consistency in the general examination environment. Each of the 3 pending office actions represents a significant portion of the company's active USPTO matters. This decentralized structure requires practitioners to be highly adaptable to the specific feedback of the 3 distinct examiners. Since there is concentration in 2 distinct art units, the company may find some procedural commonalities across the matters. Every pending office action is highly consequential for the firm's overall intellectual property position in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837378 | NOVEL THR BETA ANALOGS AND USES THEREOF | AGGARWAL, SAHIL CHANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19303585 | SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE | MOU, LIYUAN | 7d |
| 18032895 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | VALENROD, YEVGENY | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19303585 | SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE | MOU, LIYUAN | 1628 | §102DP | Final Rejection | 7d | Pending | Aug 19, 2025 |
| 18837378 | NOVEL THR BETA ANALOGS AND USES THEREOF | AGGARWAL, SAHIL CHANDER | 1623 | §103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18032895 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | VALENROD, YEVGENY | 1628 | §112 | Non-Final OA | — | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMadrigal Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Liyuan Mou has the most, with 1 of Madrigal Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
